McDermott and Bull executive Search
 

Other News

Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies

Financial by 0 comments

SINGAPORE, June 18, 2021 /PRNewswire/ — Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion of an oversubscribed $24 million Series A financing round. The round was co-led by EVX Ventures and Boehringer Ingelheim Venture Fund (BIVF), with EDBI, Xora Innovation, SEEDS Capital and other investors joining the syndicate. The […]

Continue Reading →

Rancho Santa Fe Bio, Inc. Enters into Worldwide Exclusive License Agreement with Sanofi for Ataciguat

Coronary/Structural Heart by 0 comments

SAN DIEGO and PARIS, June 17, 2021 (GLOBE NEWSWIRE) — Rancho Santa Fe Bio, Inc. (“RSF Bio” or the “Company”), a San Diego, California-based clinical-stage cardiovascular platform company, today announced that it has entered into an exclusive worldwide license agreement with Sanofi, a global biopharmaceutical company. This agreement provides RSF […]

Continue Reading →

PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab

Financial by 0 comments

Agreement provides PhaseBio with $20 million upfront payment and eligibility to receive up to $245 million in development and commercial milestones in addition to tiered double digit royalties on sales Collaboration reinforces global bentracimab opportunity Establishes accessibility to bentracimab, if approved, for the largest pool of ticagrelor patients in the […]

Continue Reading →

United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review

Regulatory Rhythm by 0 comments

FDA action expected in October 2021 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 16, 2021 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review the New Drug Application (NDA) for Tyvaso DPI™ (inhaled treprostinil) for the treatment of pulmonary arterial hypertension […]

Continue Reading →

MedTech Innovator Unveils Top 50 Medtech Startups Selected for Annual Showcase and Accelerator

Financial by 0 comments

LOS ANGELES — June 15, 2021 — MedTech Innovator, the largest accelerator of medical device companies in the world, today announced the 50 companies selected to participate in the organization’s flagship four-month Showcase and Accelerator program, featuring the industry’s most transformative device, diagnostic, and digital health technologies from around the […]

Continue Reading →

Artio Medical Hires Key Sales and Marketing Leaders to Prepare for Commercial Launch of First Product in U.S.

Financial by 0 comments

PRAIRIE VILLAGE, Kas., June 15, 2021 /PRNewswire/ — Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announced the hiring of Jeff Weinrich as Head of Global Sales and Chris Parker as Senior Director of Marketing. Weinrich and Parker have joined Artio to prepare the company […]

Continue Reading →

Mezzion Appoints William Breitenbach as Chief Commercial Officer for Mezzion’s Global Commercial Operations

Financial by 0 comments

SEOUL, Republic of Korea, June 15, 2021 /PRNewswire/ — Mezzion Pharma Co., Ltd. (140410.KQ), and Mezzion Pharmaceuticals, Inc. (individually or collectively, “Mezzion”), a leader in the field of rare single ventricle congenital heart disease (“SVHD”) and SVHD patients with Fontan circulation, is pleased to announce that Bill Breitenbach has joined Mezzion as the Chief Commercial […]

Continue Reading →

Dutch MedTech STENTiT appoints Golo von Basum as Chief Operating Officer

Financial by 0 comments

EINDHOVEN, Netherlands, June 15, 2021 /PRNewswire/ — STENTiT, a medical device company bringing a novel class of regenerative stents for sustained endovascular repair, has appointed Dr. Golo von Basum (picture) as its Chief Operating Officer (COO). He will be responsible for the strategic implementation to scale and standardize the product development and company operations. […]

Continue Reading →

Establishing TAVR for the Treatment of Aortic Regurgitation(1)

Coronary/Structural Heart by 0 comments

JenaValve Marks the 100th Implant of the Trilogy™ Heart Valve System IRVINE, Calif., June 15, 2021 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer, and manufacturer of a novel transcatheter aortic valve replacement (TAVR) system, is pleased to announce today the 100th global implant of the Trilogy™ Heart Valve System. This milestone […]

Continue Reading →
1 2 3 … 586